Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Atropine
Drug ID BADD_D00189
Description An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae.
Indications and Usage For the treatment of poisoning by susceptible organophosphorous nerve agents having anti-cholinesterase activity (cholinesterase inhibitors) as well as organophosphorous or carbamate insecticides.
Marketing Status approved; vet_approved
ATC Code A03BA01; S01FA01
DrugBank ID DB00572
KEGG ID D00113
MeSH ID D001285
PubChem ID 174174
TTD Drug ID D0RG3O
NDC Product Code 69205-034; 11704-101; 13371-488; 11704-104; 11704-107; 11704-105; 12714-034; 11704-106; 60592-049; 63827-1015; 64181-0048
UNII 7C0697DR9I
Synonyms Atropine | Atropinol | Atropine Sulfate | Sulfate, Atropine | Atropine Sulfate Anhydrous | Anhydrous, Atropine Sulfate | Sulfate Anhydrous, Atropine | AtroPen | Atropin Augenöl | Augenöl, Atropin
Chemical Information
Molecular Formula C17H23NO3
CAS Registry Number 51-55-8
SMILES CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.001--
Abdominal pain07.01.05.002--
Accommodation disorder06.02.04.001--Not Available
Agitation19.06.02.001; 17.02.05.0120.000482%
Amnesia19.20.01.001; 17.03.02.001--
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000207%
Anaphylactic shock24.06.02.004; 10.01.07.0020.000138%Not Available
Angina pectoris24.04.04.002; 02.02.02.002--
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009--Not Available
Angle closure glaucoma06.03.01.001--Not Available
Anhidrosis23.02.03.001--Not Available
Anticholinergic syndrome17.05.01.0010.000620%Not Available
Anxiety19.06.02.002--
Arrhythmia supraventricular02.03.03.001--Not Available
Asthenia08.01.01.001--Not Available
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.0020.000138%
Atrial tachycardia02.03.03.004--
Blepharitis23.03.04.012; 06.04.04.001--Not Available
Blindness06.02.10.003; 17.17.01.003--Not Available
Blood pressure increased13.14.03.005--Not Available
Blood urea increased13.13.01.006--Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.000207%Not Available
Cardiac arrest02.03.04.0010.000344%
Cerebellar syndrome17.02.02.002--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.12.02.003--Not Available
Choroidal detachment12.01.04.006; 06.09.01.0030.000138%Not Available
Clonus17.02.05.002--Not Available
Coma17.02.09.0010.000138%Not Available
The 1th Page    1 2 3 4 5    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene